DISCOVER-ATTR
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive and life-threatening disease that remains largely under-recognized, under-diagnosed, and under-treated. It can be inherited or caused by abnormal deposition of wild-type transthyretin. New pharmacological therapies have shown promise in altering the disease trajectory and improving patient outcomes. However, there is a critical need for comprehensive data on patient characteristics and care patterns to enhance early diagnosis and treatment.
About the study
DISCOVER-ATTR Pilot Study is a single-center observational registry aimed at piloting the development of a decentralized, patient-powered digital registry for transthyretin amyloid cardiomyopathy (ATTR-CM). This study will capture multimodal patient data from electronic health records (EHRs) and wearable devices to evaluate the feasibility of remote patient enrollment and data collection.
-
You may qualify if you are attending a participating clinic at an enrolling site and:
Are over 18 years of age at the first visit.
Have a clinical diagnosis of ATTR amyloid cardiomyopathy
-
Participants will:
Electronically consent to join the study.
Share their EHR data through the Hugo Health platform.
Link their wearable device data to the registry via the CarDS Plus app.
-
Participants will receive a $50 prepaid electronic Visa gift card upon completing the data linkage process.
